Despite responsiveness to both chemotherapy and radiation therapy, most patients with low grade non-Hodgkin's lymphoma (NHL) die as a consequence of the disease. Chlorambucil (CB) alone yields responses in approximately seventy-five percent of patients with a median duration of first remission of one to two years. However, although subsequent remissions can often be achieved, the characteristic continuous relapse pattern results in a median survival of between five and ten years (Jones et al., 1973; Young et al., 1977; Lister et al., 1978; Rudders et al., 1979; Hoppe et al., 1981; Anderson et al., 1982; Gallagher et al., 1986) .
It has been demonstrated that administration of leucocyte or recombinant DNA interferon causes regression of disease in approximately forty per cent of patients with low grade lymphoma (Merigan et al., 1978; Louie et al., 1981; Ozer et al., 1983; Horning et al., 1985; Wagstaff et al., 1986) . Combinations of interferon with conventional cytotoxic agents have been investigated in murine models of leukaemia and lymphoma (Chirigos & Peason, 1973; Gresser et al., 1978; Slater et al., 1981; Tozawa et al., 1982; Mowshowitz et al., 1982) ; longer survival was observed in animals receiving the combination than in those receiving either drug alone. On the basis of these observations it was decided to investigate the concurrent administration of CB and interferon (IFN-a2) in previously treated patients with low grade NHL.
Twenty-three patients (median age 52 years, range 28-70) with recurrent, low grade NHL (11 follicular, 6 centrocytic, 4 lymphoplasmacytoid, I peripheral T cell) and 1 patient with chronic lymphocytic leukaemia received CB and IFN-ac2 as shown in Figure 1 . All, except one patient with follicular lymphoma had bone marrow infiltration at the time of Toxicity Eleven patients completed therapy at full doses with no treatment delay. The reasons for stopping treatment in the remainder were disease progression (5), myelosuppression (5), death due to septicaemia (1) and interferon intolerance (1). Myelosuppression also precluded continuation of CB in two patients at 6 and 12 weeks respectively. The flu-like symptoms experienced by most patients were similar to those previously described with interferon alone (Merigan et al., 1977; Priestman, 1980; Horning et al., 1982; Sherwin et al., 1982) . The haematological toxicity was that to be expected in such a patient population treated with CB alone (Table I) . Response Responses were observed in 14 out of 23 patients overall (1 CR, 13 PR) including 8 out of 11 patients with follicular lymphoma (1 CR, 7 PR). In 4 patients, the combination resulted in a greater degree of clinical response than had previously been observed with CB alone. This study has demonstrated that it is possible to administer CB and IFN-o2 on the schedule described to the majority of patients with follicular lymphoma and achieve responses, even if not CR, in approximately three quarters. This is encouraging considering the amount of prior therapy received. A randomised study is currently in progress in previously untreated patients with advanced follicular lymphoma to compare the combination with CB alone.
